Gain Therapeutics (GANX) Competitors $1.49 -0.06 (-3.56%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.54 +0.05 (+3.62%) As of 08/7/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. LYEL, ACRS, SLS, CLLS, VYGR, DERM, CTOR, LFVN, LIMN, and CTNMShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Lyell Immunopharma (LYEL), Aclaris Therapeutics (ACRS), SELLAS Life Sciences Group (SLS), Cellectis (CLLS), Voyager Therapeutics (VYGR), Journey Medical (DERM), Citius Oncology (CTOR), Lifevantage (LFVN), Liminatus Pharma (LIMN), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Its Competitors Lyell Immunopharma Aclaris Therapeutics SELLAS Life Sciences Group Cellectis Voyager Therapeutics Journey Medical Citius Oncology Lifevantage Liminatus Pharma Contineum Therapeutics Lyell Immunopharma (NASDAQ:LYEL) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership. Is LYEL or GANX more profitable? Gain Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -514,649.22%. Lyell Immunopharma's return on equity of -73.66% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-514,649.22% -73.66% -60.99% Gain Therapeutics N/A -247.55%-146.06% Which has preferable valuation & earnings, LYEL or GANX? Gain Therapeutics has lower revenue, but higher earnings than Lyell Immunopharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$65K2,691.90-$342.99M-$25.00-0.45Gain Therapeutics$50K896.09-$20.41M-$0.86-1.73 Do analysts recommend LYEL or GANX? Lyell Immunopharma currently has a consensus price target of $15.00, indicating a potential upside of 32.51%. Gain Therapeutics has a consensus price target of $8.20, indicating a potential upside of 450.34%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media favor LYEL or GANX? In the previous week, Gain Therapeutics had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 2 mentions for Gain Therapeutics and 0 mentions for Lyell Immunopharma. Gain Therapeutics' average media sentiment score of 1.08 beat Lyell Immunopharma's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lyell Immunopharma Neutral Gain Therapeutics Positive Which has more volatility & risk, LYEL or GANX? Lyell Immunopharma has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Do insiders & institutionals have more ownership in LYEL or GANX? 66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by company insiders. Comparatively, 7.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryGain Therapeutics beats Lyell Immunopharma on 10 of the 17 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.46M$2.51B$5.48B$9.57BDividend YieldN/A1.78%4.00%4.18%P/E Ratio-1.7319.6629.8825.14Price / Sales896.09684.52440.19102.95Price / CashN/A165.0335.9458.58Price / Book5.324.198.105.59Net Income-$20.41M$31.61M$3.26B$265.48M7 Day Performance3.47%0.95%0.65%1.22%1 Month Performance-11.31%2.90%2.44%0.39%1 Year Performance54.08%4.11%27.59%23.47% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics3.1232 of 5 stars$1.49-3.6%$8.20+450.3%+56.4%$46.46M$50K-1.7320News CoveragePositive NewsUpcoming EarningsLYELLyell Immunopharma3.3213 of 5 stars$11.37+3.2%$15.00+31.9%-59.9%$170.34M$60K-0.45270ACRSAclaris Therapeutics2.009 of 5 stars$1.56+2.0%$8.71+458.6%+31.9%$165.67M$18.72M-1.12100News CoverageEarnings ReportSLSSELLAS Life Sciences Group2.233 of 5 stars$1.59-4.2%$7.00+340.3%+36.8%$165.63M$1M-4.1810Upcoming EarningsCLLSCellectis2.2194 of 5 stars$3.02+2.4%$4.00+32.5%+31.0%$163.97M$49.22M-3.51290Earnings ReportGap UpVYGRVoyager Therapeutics3.9207 of 5 stars$3.21+8.4%$13.39+317.1%-54.3%$163.80M$80M-2.20100Analyst ForecastHigh Trading VolumeDERMJourney Medical1.7306 of 5 stars$7.14+2.1%$9.50+33.1%+48.4%$162.84M$56.13M-18.3190News CoverageUpcoming EarningsCTORCitius Oncology1.0606 of 5 stars$2.06flat$3.00+45.6%N/A$161.44MN/A0.00N/ALFVNLifevantage4.0702 of 5 stars$13.29+5.6%$30.50+129.5%+72.5%$158.36M$200.16M19.26260LIMNLiminatus PharmaN/A$5.09-14.2%N/AN/A$154.27MN/A0.00N/ACTNMContineum Therapeutics2.4425 of 5 stars$5.80-2.7%$22.50+287.9%-60.1%$154.19M$50M-2.9431Earnings ReportUpcoming Earnings Related Companies and Tools Related Companies Lyell Immunopharma Alternatives Aclaris Therapeutics Alternatives SELLAS Life Sciences Group Alternatives Cellectis Alternatives Voyager Therapeutics Alternatives Journey Medical Alternatives Citius Oncology Alternatives Lifevantage Alternatives Liminatus Pharma Alternatives Contineum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredFuturist Eric Fry says it will be a “Summer of Surge” for these three stocksWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
